

# Anna Bonjoch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4953879/publications.pdf>

Version: 2024-02-01

37  
papers

634  
citations

623734

14  
h-index

580821

25  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1092  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Ultrasound-Based Assessment of Preperitoneal Fat as a Surrogate Marker of Cardiovascular Risk: Comparative Study Between People Living with HIV and Controls. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 222-227.              | 1.1 | 1         |
| 2  | Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with HIV. <i>HIV Medicine</i> , 2022, , .   | 2.2 | 0         |
| 3  | Potential prescribing issues among older HIV-infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1310-1317.                       | 2.4 | 8         |
| 4  | Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged >70 years: a comparative cohort study (Over50 cohort). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-8. | 1.2 | 1         |
| 5  | A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. <i>PLoS ONE</i> , 2020, 15, e0238575.              | 2.5 | 3         |
| 6  | Title is missing!. , 2020, 15, e0238575.  |     | 0         |
| 7  | Title is missing!. , 2020, 15, e0238575.  |     | 0         |
| 8  | Title is missing!. , 2020, 15, e0238575.  |     | 0         |
| 9  | Title is missing!. , 2020, 15, e0238575.  |     | 0         |
| 10 | High Prevalence of Sarcopenia in HIV-Infected Individuals. <i>BioMed Research International</i> , 2018, 2018, 1-5.  | 1.9 | 36        |
| 11 | High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2452-2459.  | 3.0 | 6         |
| 12 | Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals. <i>Medicine (United States)</i> , 2017, 96, e7421.  | 1.0 | 11        |
| 13 | Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. <i>Clinical Rheumatology</i> , 2016, 35, 1271-1279.  | 2.2 | 62        |
| 14 | Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity. <i>BioMed Research International</i> , 2016, 2016, 1-5.   | 1.9 | 7         |
| 15 | Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw504.                                     | 3.0 | 9         |
| 16 | Impact of protease inhibitors on the evolution of urinary markers. <i>Medicine (United States)</i> , 2016, 95, e4507.   | 1.0 | 4         |
| 17 | Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2564-2566.  | 3.2 | 15        |
| 18 | Management of bone mineral density in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 845-852.  | 1.8 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 817-821.  | 1.1 | 10        |
| 20 | Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2104-2107.                           | 3.0 | 25        |
| 21 | Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients. <i>Antiviral Research</i> , 2015, 114, 48-52.   | 4.1 | 7         |
| 22 | Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject. <i>New Microbiologica</i> , 2015, 38, 193-9.  | 0.1 | 3         |
| 23 | Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3368-3371. | 3.0 | 43        |
| 24 | Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8.   | 1.9 | 4         |
| 25 | Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 207-212.   | 2.1 | 30        |
| 26 | High Prevalence of Signs of Renal Damage Despite Normal Renal Function in a Cohort of HIV-Infected Patients: Evaluation of Associated Factors. <i>AIDS Patient Care and STDs</i> , 2014, 28, 524-529.  | 2.5 | 16        |
| 27 | Association between lipid genetic and immunological status in chronically HIV-infected patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19555.   | 3.0 | 1         |
| 28 | Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. <i>Journal of the International AIDS Society</i> , 2014, 17, 19557.   | 3.0 | 2         |
| 29 | Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study. <i>PLoS ONE</i> , 2014, 9, e84676.               | 2.5 | 11        |
| 30 | Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1382-1387.  | 3.0 | 25        |
| 31 | Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. <i>Future Virology</i> , 2012, 7, 1127-1134.  | 1.8 | 3         |
| 32 | High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. <i>Antiviral Research</i> , 2012, 96, 65-69.  | 4.1 | 39        |
| 33 | Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. <i>PLoS ONE</i> , 2012, 7, e46031.  | 2.5 | 16        |
| 34 | Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. <i>Antiviral Research</i> , 2010, 88, 347-354.  | 4.1 | 26        |
| 35 | High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. <i>Aids</i> , 2010, 24, 2827-2833.   | 2.2 | 140       |
| 36 | Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 321-329.   | 1.1 | 48        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Antiretroviral Treatment Simplification With 3 NRTIs or 2 NRTIs Plus Nevirapine in HIV-1-Infected Patients Treated With Successful First-Line HAART. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 39, 313-316. | 2.1 | 18        |